FINWIRES · TerminalLIVE
FINWIRES

Aptiv's Growth Outside Auto Demand Supports Outlook, RBC Says

By

-- Aptiv (APTV) may benefit from rising orders from Chinese carmakers and customers outside the auto industry, while cost recoveries and stronger H2 margins could help it meet its full-year target, RBC Capital Markets said Tuesday in a report.

Aptiv's Q1 adjusted EBITDA beat expectations, driven by strength in its former electrical distribution systems unit, now spun off as Versigent (VGNT), the report said. Weakness in the intelligent systems unit partly offset the beat, with pressure from Ford (F) production disruptions and slower-than-expected progress on a major European automaker's program, RBC said.

Management maintained its full-year adjusted EBITDA guidance of $2.4 billion, though the Q2 outlook implies Aptiv will need better margins later in the year to reach that target, RBC said.

Aptiv's expansion outside autos looks positive, supported by new business wins in naval, space and energy-storage markets, though early investment may weigh on margins until the business grows, the report said.

RBC maintained its outperform rating on Aptiv stock and its $81 price target. The company should be able to manage higher commodity expenses given its strong track record of recovering most of those costs from automaker customers, the report said.

Price: $56.81, Change: $+1.98, Percent Change: +3.61%

Related Articles

Australia

Aptiv Stock Sell-off Post Q1 Results was Unwarranted, UBS Says

Aptiv (APTV) stock sell-off post Q1 results was unwarranted and likely driven by the lower-than-expected Q2 guide and rising cost pressures with 2026 more back-half weighted that appears like a steep ramp, UBS said in a Wednesday research report.While Q2 is impacted by "stranded cost" and Ford Motor (F) volume timing, H2 ramp looks more achievable than optics suggest amid positive developments in China and the non-auto segments, analysts wrote.The company expects positive growth from China in Q2, driven by new programs and normalization of production at key customer, the brokerage stated.Commodity headwinds should abate in H2 as recoveries lag, UBS said.The brokerage said it reiterated its buy rating on the stock and price target of $80 per share.Aptiv shares were up 4% in Wednesday trading.Price: $56.47, Change: $+1.64, Percent Change: +2.99%

$APTV$F
Research

Wells Fargo Downgrades Criteo to Equalweigt From Overweight, $18 Price Target

Price: $15.79, Change: $-4.34, Percent Change: -21.55%

$CRTO
Australia

Ocular Therapeutix Advances FDA Talks on Single-Trial Filing for Eye Drug, RBC Says

Ocular Therapeutix (OCUL) is moving closer to a potential US Food and Drug Administration filing for axpaxli, its long-acting treatment for wet age-related macular degeneration, as regulators begin formal discussions on a single-trial approval path, RBC Capital Markets said Tuesday in a report.Management said talks with the FDA are now ongoing, raising the possibility of submitting an application based on the company's successful pivotal study, rather than waiting for a second trial that is due to read out in early 2027, RBC said.The company plans to provide additional regulatory and program updates at an investor day on June 17, RBC said.Ocular continues to target a potential 2027 launch for axpaxli under a single-trial filing strategy, and RBC reiterated its view that the drug has a "positive benefit/risk profile."RBC maintained its rating of outperform, speculative risk, on Ocular stock with a $30 price target.Price: $9.84, Change: $+0.13, Percent Change: +1.29%

$OCUL